drugset
drugset / Trial / NCT00787618

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

NCT00787618 ↗

Phase 1/2 Terminated 6 enrolled Repros Therapeutics Inc.
Non-randomizedParallel-groupOpen-label

Summary

PK and safety profile of Proellex® in females with various stages of impaired renal function

Timeline

Start
2008-10
Primary completion
2009-06
Completion
2009-07

Outcome

Outcome not reported

Stopped: “Increased LFTs”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Proellex Other / unclassified 50 mg —

Indications

impaired renal function disease